On July 17, Japan’s Cabinet adopted the 2020 Basic Policy on Economic and Fiscal Management and Reform (honebuto). Its initial text suggested the government’s position to carry out its first off-year drug price revision next April as well as its…
HOME > ACADEMIA
ACADEMIA
- AMED Study Team Drafting First Guidelines for Diagnosis and Treatment of Post-Stroke Epilepsy
April 21, 2016
- 17 Japanese Medical Societies Jointly Recommend HPV Vaccines
April 20, 2016
- Positioning of Abraxane and Anti-PD-1 Antibodies Will Be Focus of Interest in Revised Guidelines for Gastric Cancer
March 23, 2016
- It’s Time to Discuss Restart of HPV Vaccine Promotion, Panel Chief Says as Personal View
March 16, 2016
- Biomarkers Urgently Needed to Tackle Ballooning Immunotherapy Costs: Oncologist
March 15, 2016
- Japan’s First Diabetes Management Guidelines for Elderly to Be Announced in May
March 11, 2016
- Development of AT2 Receptor-Related New Drugs Forging Ahead Overseas, but Japan Is “Far Behind”
February 22, 2016
- Sanofi, Univ. of Tokyo Form Strategic Partnership on Drug Discovery Research
February 19, 2016
- Discussions on New Guidelines for Atherosclerosis Prevention Get Underway
February 9, 2016
- Japan Oncology Society Calls for Proper Use of Opdivo
January 22, 2016
- Experts Launch Japanese Society of Geriatric Pharmacy
January 7, 2016
- Shionogi Funding Research to Develop World’s First Drug for Preventing Postoperative Metastasis of Lung Cancer
January 5, 2016
- Over 200 Medical Institutions, 14 Drug Makers Participating in Project to Analyze Cancer-Related Genetic Disorders
December 14, 2015
- Viekirax Joins Fray in Hep C Market, Can It Crack into Harvoni’s Stronghold?
November 20, 2015
- Japan Geriatrics Society to Publish Guidelines for Safe Pharmacotherapy in the Elderly Next Month
November 18, 2015
- Japan Sepsis Management Guidelines to Be Revised Next Year
October 27, 2015
- Group Calls for Appropriate Dosing of Dementia Drugs
October 9, 2015
- Asia, Oceania Obesity Associations Adopt Declaration on “Obesity Disease”
October 6, 2015
- New Guidelines for Obesity Treatment to Set Thresholds to Evaluate Drugs
October 6, 2015
- Japan Hypertension Society Announces COI Guide after Diovan Woes
October 5, 2015
ページ
Since last year, Japan has seen a number of stock-outs and shortages of generic drugs attributable to API supply disruptions…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…